Prescribing for gout: a second option

FEBUXOSTAT is subsidised under the PBS for second-line therapy in people with chronic symptomatic gout.1,2

Consider prescribing febuxostat in patients who are hypersensitive to, or intolerant of, allopurinol, or in cases where allopurinol is contraindicated.1

Febuxostat is a non-purine selective inhibitor of xanthine oxidase which decreases serum uric acid level compared to placebo.3

The starting dose for febuxostat is 40mg, taken once daily.2

Given that only the 80mg tablet is marketed in Australia